Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member constituency
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member constituency answering member printed grouped question UIN question first answered question first ministerially corrected answering member label attachment file name title previous answer version answering member constituency answering member printed answering member label
tabling member	label

Search

1126321

	registered interest
	date	13/05/2019
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Gender Dysphoria: Children
	house id	2
	legislature	25277 pref label House of Lords
	question text	To ask Her Majesty's Government whether they intend to publish the results of the research project started in 2011 by the NHS Gender Identity Development Service Early pubertal suppression in a carefully selected group of adolescents with gender identity disorder; and if not, whether they will arrange for the data gathered by that study to be made available to other researchers.
	tabling member printed	Lord Lucas
	uin	HL15681
	answer	answer is ministerial correction date of answer 22/05/2019 answer text <p>The research is an ethically approved study being carried out by the Tavistock and Portman NHS Foundation Trust since 2011, which is the largest provider of services for the alleviation of gender dysphoria in the United Kingdom.</p><p>The study will evaluate early pubertal suppression in a carefully selected group of adolescents with a clinical diagnosis of gender dysphoria. There are 44 young people taking part in the study.</p><p>The Tavistock and Portman NHS Foundation Trust has plans to publish the data <ins class="ministerial">on the blocker and cross-sex hormones, for those who were appropriate for this, as</ins><del class="ministerial">once</del> all of the young people in the study have reached <ins class="ministerial">this</ins><del class="ministerial">the</del> stage<ins class="ministerial">.</ins> <del class="ministerial">when a clinical decision is made about moving from pubertal suppressants to cross-sex hormones, which the Trust expects to occur in the next 12 months.</del></p> answering member printed Baroness Blackwood of North Oxford question first answered 22/05/2019 14:51:30 question first ministerially corrected 31/07/2019 15:30:59 answering member 4019 label Biography information for Baroness Blackwood of North Oxford previous answer version 119577 answering member printed Baroness Blackwood of North Oxford answering member 4019 label Biography information for Baroness Blackwood of North Oxford
	tabling member	1879 label Biography information for Lord Lucas

1128442

	registered interest
	date	23/05/2019
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Cannabis: Medical Treatments
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, if he will publish the evidence (a) his Department and (b) the Department for International Trade holds on growing a market for prescribed medicinal cannabis.
	tabling member constituency	Hemel Hempstead
	tabling member printed	Sir Mike Penning
	uin	257706
	answer	answer is ministerial correction date of answer 10/06/2019 answer text <p><ins class="ministerial"> <p><ins class="ministerial">The Department for International Trade and the Department of Health and Social Care are not specifically collecting data on the growth of the market for cannabis based products for medicinal use in the United Kingdom.</ins></p><p><ins class="ministerial">However, data from the Medicines and Healthcare products Regulatory Agency (MHRA) shows growing numbers of import notifications for medicinal cannabis and the Home Office has received increased numbers of licence applications.</ins></p><p><ins class="ministerial">In addition, UK companies exporting these products and foreign companies looking to invest in the UK have full access to government support, where they have the necessary authorisations from the MHRA and Home Office and a relevant Export Licence.</ins></p></ins></p><p><del class="ministerial">An initial impact assessment was published alongside The Misuse of Drugs (Amendments) (Cannabis and Licence Fees) (England, Wales and Scotland) Regulations 2018. This can be viewed at the following link:</del></p><p><del class="ministerial"><a href="http://www.legislation.gov.uk/uksi/2018/1055/impacts" target="_blank">http://www.legislation.gov.uk/uksi/2018/1055/impacts</a></del></p><p><del class="ministerial">This set out the approach that the Government proposed to take in assessing the costs and benefits of the change in the law at a population level, with regard to the rescheduling of cannabis-based products for medicinal use (CBPM). This framework included potential savings in treatment costs, giving the example of patients with severe epilepsy for whom medicinal use of cannabis could reduce the frequency of seizures and reduce the number of related hospital admissions. This was an initial framework for assessing this policy and as we develop our knowledge in this area, both on the costs and the potential benefits, we can revisit and refine these assessments.</del></p><p><del class="ministerial">In the meantime, the National Institute for Health and Care Excellence (NICE) is developing clinical guidelines on the appropriate use of CBPM based on the best available evidence, and the National Institute for Health Research is funding further clinical research on this. More information is available at the following link:</del></p><p><del class="ministerial"><a href="https://www.nihr.ac.uk/funding-and-support/documents/themed-calls/cannabis-based%20products/cannabis-based-products-brief.pdf" target="_blank">https://www.nihr.ac.uk/funding-and-support/documents/themed-calls/cannabis-based%20products/cannabis-based-products-brief.pdf</a></del></p> answering member constituency South Ribble answering member printed Seema Kennedy question first answered 10/06/2019 13:18:03 question first ministerially corrected 11/06/2019 11:31:21 answering member 4455 label Biography information for Seema Kennedy previous answer version 121340 answering member constituency South Ribble answering member printed Seema Kennedy answering member 4455 label Biography information for Seema Kennedy
	tabling member	1528 label Biography information for Sir Mike Penning

1129191

	registered interest
	date	03/06/2019
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Prescription Drugs
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, how many prescriptions of (a) individual benzodiazepine drugs and (b) individual antidepressants were dispensed in the community in 2018.
	tabling member constituency	Bristol North West
	tabling member printed	Darren Jones
	uin	259400
	answer	answer is ministerial correction date of answer 11/06/2019 answer text <p>Information on the number of prescription items from the Prescription Cost Analysis system for benzodiazepines and antidepressants written in the United Kingdom and dispensed in the community in England, for the year 2018 can be found in the attached tables.</p><p>The data available is at prescription item level by presentation. Prescriptions are prescribed either by a paper prescription form or via an Electronic Prescription Service message. Each single item written on the form is counted as a prescription item. No information is available for those prescriptions written but not dispensed.</p> answering member constituency South Ribble answering member printed Seema Kennedy question first answered 11/06/2019 16:51:00 question first ministerially corrected 12/06/2019 14:34:05 answering member 4455 label Biography information for Seema Kennedy attachment 1 file name PQ259400 table formatted.docx title Prescription data benzodiazipines & antidepressant previous answer version 122124 answering member constituency South Ribble answering member printed Seema Kennedy answering member 4455 label Biography information for Seema Kennedy
	tabling member	4621 label Biography information for Darren Jones

1132035

	registered interest
	date	13/06/2019
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Primary Care Networks
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, what the requirements for primary care networks to engage with the local community will be.
	tabling member constituency	Newton Abbot
	tabling member printed	Anne Marie Morris
	uin	264406
	answer	answer is ministerial correction date of answer 18/06/2019 answer text <p><ins class="ministerial"> <p><ins class="ministerial">Primary Care Networks (PCNs) are a new way for primary and community service organisations to work together. For PCNs to be successful they will need to work in partnership with local people and the communities they serve. Legal duties which currently apply to NHS service providers - including general practitioner practices - and commissioners around engagement and consultation will continue to be valid for PCNs.</ins></p></ins></p><p><del class="ministerial">NHS England and NHS Improvement, together with the National Institute for Health and Care Excellence, is developing a ’commercial framework’ setting out the parameters for the commercial approach for medicines in the health service in England.</del></p><p><del class="ministerial">The commercial framework will support a single, transparent, robust and integrated pricing and market access process, and is being tested with and informed through consultation with stakeholders including the Association of the British Pharmaceutical Industry.</del></p><p><del class="ministerial">In preparation for public consultation in the coming months, NHS England is actively engaging with industry trade bodies and health system partners, in the first instance, to outline progress on the development of the commercial framework. The consultation on the draft framework is anticipated to be launched in Quarter 3 2019 with consultation events to be held in Manchester and London, and implementation of the commercial framework is expected to follow.</del></p> answering member constituency South Ribble answering member printed Seema Kennedy question first answered 18/06/2019 16:34:05 question first ministerially corrected 19/06/2019 08:36:30 answering member 4455 label Biography information for Seema Kennedy previous answer version 123829 answering member constituency South Ribble answering member printed Seema Kennedy answering member 4455 label Biography information for Seema Kennedy
	tabling member	4249 label Biography information for Anne Marie Morris

1125504

	registered interest
	date	08/05/2019
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Pneumococcal Diseases: Vaccination
	house id	2
	legislature	25277 pref label House of Lords
	question text	To ask Her Majesty's Government what assessment they have made of the recommendations by the Joint Committee on Vaccination and Immunisation to reduce the infant pneumococcal vaccination schedule from three doses to two.
	tabling member printed	Baroness Masham of Ilton
	uin	HL15599
	answer	answer is ministerial correction date of answer 22/05/2019 answer text <p>The Joint Committee on Vaccination and Immunisation (JCVI) provides independent expert advice on the United Kingdom’s immunisation programme. As an independent committee, it is well placed to ensure the latest and most appropriate evidence has been considered on potential changes to scheduling within the vaccine programme. It bases its advice on review of a wide range of scientific and other evidence, including from the published literature, commissioned studies such as independent analyses of vaccine effectiveness and cost effectiveness.</p><p>The JCVI advised that a two-dose schedule for the infant pneumococcal conjugate vaccine (PCV) Prevenar13 is appropriate for the UK. Its advice takes into account the public health aspects of any potential change to the vaccination schedule, such as the potential impact on cases of infectious disease. The JCVI consulted relevant stakeholders on its proposed advice, between January and April 2018, to ensure that its advice reflects all the evidence.</p><p>The JCVI’s advice on the infant pneumococcal programme was given full consideration, including the potential public health implications, before a decision was made to implement it. The UK frequently adopts innovative immunisation schedules and we regularly change the vaccine schedule following the advice of our independent expert committee, as we are doing in this case.</p><p>The decision is based on the excellent effectiveness of the vaccine and years of high uptake, which has helped to provide protection to the rest of the population and has successfully controlled many types of pneumococcal disease in this country. The evidence shows that two doses will sustain the excellent results we have already seen. We are confident that the world-class disease surveillance system we have in this country means our expert committee can closely monitor the impact of this change. This is set out in the JCVI’s minutes which are attached.</p> answering member printed Baroness Blackwood of North Oxford grouped question UIN HL15600 question first answered 22/05/2019 14:50:14 answering member 4019 label Biography information for Baroness Blackwood of North Oxford attachment 1 file name JCVI Minute 2015 10 Attached to HL16000 and 15999.pdf title JCVI Minute 2015
	tabling member	1850 label Biography information for Baroness Masham of Ilton

1125505

	registered interest
	date	08/05/2019
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Pneumococcal Diseases: Vaccination
	house id	2
	legislature	25277 pref label House of Lords
	question text	To ask Her Majesty's Government what analyses they have conducted of the risks and benefits of reducing the infant pneumococcal vaccination schedule from 2+1 to 1+1; and whether they will publish the results any such analyses.
	tabling member printed	Baroness Masham of Ilton
	uin	HL15600
	answer	answer is ministerial correction date of answer 22/05/2019 answer text <p>The Joint Committee on Vaccination and Immunisation (JCVI) provides independent expert advice on the United Kingdom’s immunisation programme. As an independent committee, it is well placed to ensure the latest and most appropriate evidence has been considered on potential changes to scheduling within the vaccine programme. It bases its advice on review of a wide range of scientific and other evidence, including from the published literature, commissioned studies such as independent analyses of vaccine effectiveness and cost effectiveness.</p><p>The JCVI advised that a two-dose schedule for the infant pneumococcal conjugate vaccine (PCV) Prevenar13 is appropriate for the UK. Its advice takes into account the public health aspects of any potential change to the vaccination schedule, such as the potential impact on cases of infectious disease. The JCVI consulted relevant stakeholders on its proposed advice, between January and April 2018, to ensure that its advice reflects all the evidence.</p><p>The JCVI’s advice on the infant pneumococcal programme was given full consideration, including the potential public health implications, before a decision was made to implement it. The UK frequently adopts innovative immunisation schedules and we regularly change the vaccine schedule following the advice of our independent expert committee, as we are doing in this case.</p><p>The decision is based on the excellent effectiveness of the vaccine and years of high uptake, which has helped to provide protection to the rest of the population and has successfully controlled many types of pneumococcal disease in this country. The evidence shows that two doses will sustain the excellent results we have already seen. We are confident that the world-class disease surveillance system we have in this country means our expert committee can closely monitor the impact of this change. This is set out in the JCVI’s minutes which are attached.</p> answering member printed Baroness Blackwood of North Oxford grouped question UIN HL15599 question first answered 22/05/2019 14:50:14 answering member 4019 label Biography information for Baroness Blackwood of North Oxford attachment 1 file name JCVI Minute 2015 10 Attached to HL16000 and 15999.pdf title JCVI Minute 2015
	tabling member	1850 label Biography information for Baroness Masham of Ilton

1125506

	registered interest
	date	08/05/2019
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	HIV Infection: Vaccination
	house id	2
	legislature	25277 pref label House of Lords
	question text	To ask Her Majesty's Government what steps they are taking to improve vaccination coverage for people living with HIV.
	tabling member printed	Baroness Masham of Ilton
	uin	HL15601
	answer	answer is ministerial correction date of answer 22/05/2019 answer text <p>Public Health England, in partnership with NHS England and the Department, is taking steps to improve vaccination coverage in England, including for people living with HIV.</p><p>These steps include initiatives to improve access to the immunisation programme; communication with the public; data to identify underserved individuals and populations; and training for healthcare professionals, changes to vaccination eligibility criteria; launching disease elimination strategies; running targeted social media campaigns; providing information leaflets in multiple languages and running e-learning programme for healthcare practitioners.</p><p>Certain vaccines are delivered through sexual health services that particularly benefit people living with HIV. This includes vaccines for hepatitis A, hepatitis B and human papillomavirus. People living with HIV are in the influenza risk groups and are invited for the flu vaccine on an annual basis.</p> answering member printed Baroness Blackwood of North Oxford question first answered 22/05/2019 14:50:46 answering member 4019 label Biography information for Baroness Blackwood of North Oxford
	tabling member	1850 label Biography information for Baroness Masham of Ilton

1125517

	registered interest
	date	08/05/2019
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	NHS: Migrant Workers
	house id	2
	legislature	25277 pref label House of Lords
	question text	To ask Her Majesty's Government what plans they have, if any, to increase the number of NHS staff recruited from EU member states after Brexit.
	tabling member printed	Lord Taylor of Warwick
	uin	HL15612
	answer	answer is ministerial correction date of answer 22/05/2019 answer text <p>The Government recognises the need to be able to recruit effectively from abroad and the Immigration White Paper, <em>The UK’s future skills-based immigration system</em>, published in December 2018, sets out the foundation for a single immigration system, where it is workers’ skills that matter, not where they come from. This system will streamline the high-skilled visa route, by removing the Resident Labour Market Test and the Tier 2 Visa Cap. The Home Office is undertaking a programme of engagement to discuss the proposed measures with colleagues across Government and industry, to develop a future immigration system that works for the whole of the United Kingdom.</p><p>The Government wants to support the National Health Service in expanding international recruitment more widely, as this clearly has a role to play to meeting staffing shortages, especially in the short term. Recruitment of doctors and nurses is the responsibility of individual NHS organisations, a number of which do actively recruit from overseas, including from countries in the European Union. However, we also recognise the need to boost our domestic workforce as well. The NHS Long Term Plan sets out a vital strategic framework to ensure that, over the next 10 years, the NHS will have the staff it needs so that nurses and doctors are working in a supportive culture that allows them to provide the expert compassionate care they are committed to providing. Details of this will be explored more fully in the forthcoming Interim NHS People Plan.</p><p>The Government has taken steps to ensure that EU citizens can continue to come and work in the NHS once we have left the EU. In March 2019, we put in place legislation that ensures the continued recognition of qualifications from EU countries by all professional regulators covering the health and social care sectors. This means that EU citizens will continue to be able to come and practice in the UK once we have left the EU, even if we leave without a deal.</p> answering member printed Baroness Blackwood of North Oxford question first answered 22/05/2019 14:54:38 answering member 4019 label Biography information for Baroness Blackwood of North Oxford
	tabling member	1796 label Biography information for Lord Taylor of Warwick

1125835

	registered interest
	date	09/05/2019
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Dental Health: Antibiotics
	house id	2
	legislature	25277 pref label House of Lords
	question text	To ask Her Majesty's Government, further to the Written Answer by Lord O'Shaughnessy on 4 December 2018 (HL11750), how many antibiotic prescriptions were issued by general dental practitioners in England in 2018.
	tabling member printed	Lord Colwyn
	uin	HL15625
	answer	answer is ministerial correction date of answer 22/05/2019 answer text <p>The Dental Prescribing Dashboard developed by the NHS Business Services Authority and Public Health England, includes data for National Health Service local area teams. Latest available data show general dental practitioners issued 2,912,579 prescriptions for all antimicrobials including antibiotics during April 2017 to March 2018. There were 715,545 prescriptions between January and March 2018. The Dental Prescribing Dashboard will be refreshed in summer 2019.</p><p>Analysis is based on items prescribed by NHS dentists, but some patients may attend a general medical practice with a dental infection and receive a prescription from their general practitioner (GP). These prescriptions are not included, as we cannot determine the reason why a GP prescribed antibiotics.</p><p>The <em>English Surveillance Programme for Antimicrobial Utilisation and Resistance (ESPAUR) Report 2018</em> provides information on NHS dental prescribing in dental practices and consultations. The ESPAUR report for 2019 scheduled for publication later this year will publish data for the 2018 calendar year. The ESPAUR 2018 report is attached.</p> answering member printed Baroness Blackwood of North Oxford question first answered 22/05/2019 14:52:22 answering member 4019 label Biography information for Baroness Blackwood of North Oxford attachment 1 file name ESPAUR_2018_report.pdf title ESPAUR_2018_report
	tabling member	3394 label Biography information for Lord Colwyn

1126194

	registered interest
	date	13/05/2019
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Urinary Tract Infections: Medical Treatments
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, what assessment he has made of the efficacy of Professor James Malone-Lee's approach to treating urinary tract infections.
	tabling member constituency	Tooting
	tabling member printed	Dr Rosena Allin-Khan
	uin	253693
	answer	answer is ministerial correction date of answer 21/05/2019 answer text <p>The National Institute for Health and Care Excellence published guidance on recurrent ‘Urinary Tract Infections antimicrobial prescribing’ in October last year. This guideline sets out an antimicrobial prescribing strategy for preventing recurrent urinary tract infections in children, young people and adults who do not have a catheter. It aims to optimise antibiotic use and reduce antibiotic resistance.</p> answering member constituency South Ribble answering member printed Seema Kennedy question first answered 21/05/2019 16:21:41 answering member 4455 label Biography information for Seema Kennedy
	tabling member	4573 label Biography information for Dr Rosena Allin-Khan